-
Genentech Quest Aimed At Sparking a ‘Holy Moly’ Pivot in Neuro R&D
Hi All, came across another company, Genentech, hoping to use new technology and fresh scientific insights to generate a pipeline of drugs for neurological diseases. Unfortunately, quoting the article “…looking back a decade or two from now and saying, ‘Holy moly!” Ten to 20 years doesn’t sound too promising for today’s ALS suffers.
Richard
Sorry, there were no replies found.
Log in to reply.